Loading…
Sunrest Lifescience (SUNREST)₹35.70+0.56%Pharmaceuticals
In the Mar 2026 quarter (consolidated), Sunrest Lifescience reported sales of ₹36.76 Cr and net profit of ₹6.56 Cr. For the year to Mar 2026, sales were ₹70.71 Cr and net profit ₹7.99 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Sep 2024 | Sep 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 15.36 | 34.00 | 36.76 |
| Expenses | 14.52 | 31.65 | 30.17 |
| Operating Profit | 0.92 | 2.46 | 6.74 |
| OPM % | 5.9% | 7.2% | 18.3% |
| Other Income | 0.00 | 0.00 | 2.52 |
| Interest | 0.11 | 0.71 | 0.69 |
| Depreciation | 0.02 | 0.69 | 0.52 |
| Profit before tax | 0.77 | 1.04 | 8.04 |
| Tax % | 24.4% | 37.2% | 18.5% |
| Net Profit | 0.57 | 0.65 | 6.56 |
| EPS (Rs) | 0.68 | 0.41 | 3.94 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Sales | 33.35 | 70.71 |
| Expenses | 30.49 | 60.82 |
| Operating Profit | 3.02 | 10.20 |
| OPM % | 9.0% | 14.4% |
| Other Income | 0.00 | 2.52 |
| Interest | 0.30 | 1.41 |
| Depreciation | 0.11 | 1.20 |
| Profit before tax | 2.61 | 10.09 |
| Tax % | 23.3% | 20.9% |
| Net Profit | 2.01 | 7.99 |
| EPS (Rs) | 2.35 | 4.80 |
| Dividend payout % | 0.0% | 0.0% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 4.28 | 4.28 |
| Reserves | 12.01 | 16.12 |
| Borrowings | 12.07 | 17.51 |
| Other Liabilities | 30.36 | 33.54 |
| Total Liabilities | 58.72 | 71.45 |
| Fixed Assets | 4.38 | 8.58 |
| CWIP | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 |
| Other Assets | 54.34 | 62.87 |
| Inventories | 9.63 | 17.07 |
| Trade receivables | 36.52 | 32.55 |
| Cash & equivalents | 1.75 | 2.77 |
| Total Assets | 58.72 | 71.45 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from operating activity | 2.93 | −0.06 |
| Cash from investing activity | −1.14 | −2.90 |
| Cash from financing activity | −0.32 | 3.98 |
| Net cash flow | 1.44 | 1.02 |
| Capex | 1.36 | 7.51 |
| Free cash flow | 1.77 | −2.77 |
| CFO / OP % | 112.0% | 14.0% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor days | 397 | 167 |
| Inventory days | 174 | 140 |
| Days payable | 418 | 174 |
| Cash conversion cycle | 157 | 136 |
| Working capital days | 228 | 156 |
| ROCE % | — | 28.5% |
For the Mar 2026 quarter, Sunrest Lifescience reported sales of ₹36.76 Cr and net profit of ₹6.56 Cr. The operating margin was 18.3%.
Sunrest Lifescience's sales for the year to Mar 2026 were ₹70.71 Cr.
Net profit for the year to Mar 2026 was ₹7.99 Cr. Earnings per share over the same trailing period were ₹4.80.
Sunrest Lifescience reported borrowings of ₹17.51 Cr at Mar 2026, against cash and equivalents of ₹2.77 Cr.
Cash from operations was −₹0.06 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹2.77 Cr.